Mogamulizumab-induced bone granuloma

Affiliations

¹ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France. Electronic address: camille.alaterre@chu-lille.fr.
² Rhumatology Department, Salengro Hospital, Lille, France.
³ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France.
⁴ Internal Medicine Department, Claude-Huriez Hospital, Lille, France.
⁵ Anathomopathology Department, Pathology Institute, Lille, France.
⁶ Hematology Department, Claude-Huriez Hospital, Lille, France.
⁷ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France; Dermatology Department, Roubaix, France.
⁸ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France; Dermatology Department, Douai, France.

Camille Alaterre et al. Joint Bone Spine. 2025 Jan.

. 2025 Jan;92(1):105782.

doi: 10.1016/j.jbspin.2024.105782. Epub 2024 Sep 25.

¹ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France. Electronic address: camille.alaterre@chu-lille.fr.
² Rhumatology Department, Salengro Hospital, Lille, France.
³ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France.
⁴ Internal Medicine Department, Claude-Huriez Hospital, Lille, France.
⁵ Anathomopathology Department, Pathology Institute, Lille, France.
⁶ Hematology Department, Claude-Huriez Hospital, Lille, France.
⁷ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France; Dermatology Department, Roubaix, France.
⁸ Dermatology Department, Claude-Huriez Hospital, University of Lille, Inserm U 1189, rue Michel-Polonowski, 59000 Lille, France; Dermatology Department, Douai, France.

No abstract available

Keywords: Adverse event; Bone granuloma; CCR4; Mogamulizumab; Mogamulizumab-associated rash; Mycosis fungoides; PTCL; Sezary syndrome.

Publication types